Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Intravenous Immunoglobulin Market, By Disease Types, By Route And Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025

Published by AnalystView Market Insights Product code 737924
Published Content info 109 Pages
Delivery time: 2-3 business days
Price
Back to Top
Intravenous Immunoglobulin Market, By Disease Types, By Route And Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025
Published: December 13, 2017 Content info: 109 Pages
Description

Report Hightlights

The intravenous immunoglobulin market is estimated to represent a global market of USD 8,306 million by 2017 with growth rate of 6.3%. Intravenous immunoglobulin (IVIG) is an antibody-based product that can be administered intravenously. It contains the pooled immunoglobulin G, derived from the plasma. In terms of types, these products are categorized as immunoglobulin A, immunoglobulin G, immunoglobulin M, immunoglobulin D, and immunoglobulin E, divided based on the variety of heavy chain these molecules contain. IVIG therapy is basically indicated to the patients with humoral immunodeficiency or whose body does not produce enough antibodies. IVIG therapy act by providing extra antibodies which last for several weeks and help patients to fight against various infectious diseases. Alternatively, the immunoglobulin therapy can provide through subcutaneous route (as an injection under the skin) or intramuscular route.

Market Dynamics:

Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) are preferred for treatment of autoimmune diseases. The growth of this market is primarily attributed to the increasing incidences bleeding and autoimmune disorders, aging population, and development of new treatment indications such as myasthenia gravis. However, high cost coupled with stringent regulations associated with IVIG therapy hampers the market growth over the future period.

Disease Types Takeaway:

IVIG therapy is widely used for the treatment of many autoimmune diseases. Based on the disease types, the market is divided as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Hypogammaglobulinemia, Congenital AIDS, Immunodeficiency diseases, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, and others. In 2017, Hypogammaglobulinemia is considered to be the largest market, accounted for the 1.6 billion during the same year. It is an immune disorder, characterized by the low level of immunoglobulin and mature B-lymphocytes and plasma cells. This condition can be treated by the replacement of immunoglobulin by subcutaneous or intravenous therapies with antibiotics. IVIG therapy for the treatment of Congenital AIDS is growing significantly, i.e. 7.9% over the forecast period. In terms of route of administration, intravenous route of administration captured the largest share of the total market, around 80.1% in 2017.

Regional Takeaway:

Regionally, North America is considered to be the major market, capturing around 47% share across the year owing to the rise in the incidence of autoimmune diseases. According to the American Autoimmune Related Disease Association, Inc. (AARDA), about 50 million Americans were suffered from autoimmune diseases in the year 2012 and the number is expected to grow over the forecast period.

Developing regions such as Asia Pacific, and Latin America is accounted for the significant revenue share due to the favourable government initiatives. For example, in September 2013, Japanese Ministry of Health, Labour and Welfare have approved Hizentra, subcutaneous immunoglobulin therapy.

Key Vendor Takeaway:

Companies such as Shire, Octapharma, CSL. Grifols and others are profiled in a study. Increasing research and development initiatives coupled with growing revenue generation from IVIG business by leading players have attracted many companies to invest in this market. For example, CSL recorded around USD 2,320 million from its immunoglobulin business segment in 2014, up 12% compared to the previous year.

In March 2010, the U.S. FDA approved Hizentra, company's subcutaneous immunoglobulin product which has contributed strong sale in the U.S. and European market. Strong growth is majorly attributed to its convenience in self-administration along with the introduction of co-pay relief program. In addition to this, the recent approval of Hizentra for treatment of primary and secondary immune deficiencies in Japan coupled with the expansion of bi-weekly administration label in the U.S. market has supported the revenue generation. Furthermore, the company achieved strong growth with Privigen and Carimune sale in the Europe and America respectively.

Table of Contents
Product Code: AV147

TABLE OF CONTENTS

1. INTRAVENOUS IMMUNOGLOBULIN MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Base Year
  • 1.3. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Key Market Facts
  • 2.2. Geographical Scenario
  • 2.3. Companies in the Market

3. INTRAVENOUS IMMUNOGLOBULIN KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. INTRAVENOUS IMMUNOGLOBULIN INDUSTRY STUDY

  • 4.1. Company Activity Analysis
  • 4.2. Regulatory Framework Analysis
  • 4.3. Market Attractiveness Analysis
  • 4.4. Value Chain Analysis

5. INTRAVENOUS IMMUNOGLOBULIN MARKET LANDSCAPE

  • 5.1. Market Share Analysis
  • 5.2. Key Innovators

6. INTRAVENOUS IMMUNOGLOBULIN MARKET - BY DISEASE TYPES:

  • 6.1. Overview
  • 6.2. CIDP
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 6.3. Hypogammaglobulinemia
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 6.4. Congenital AIDS
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 6.5. Immunodeficiency diseases
    • 6.5.1. Overview
    • 6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 6.6. Chronic Lymphocytic Leukaemia
    • 6.6.1. Overview
    • 6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 6.7. Myasthenia Gravis
    • 6.7.1. Overview
    • 6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 6.8. Multifocal motor neuropathy
    • 6.8.1. Overview
    • 6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 6.9. Others
    • 6.9.1. Overview
    • 6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)

7. INTRAVENOUS IMMUNOGLOBULIN MARKET - BY ROUTE OF ADMINISTRATION:

  • 7.1. Overview
  • 7.2. Intravenous
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 7.3. Subcutaneous
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)

8. INTRAVENOUS IMMUNOGLOBULIN MARKET- BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. Overview
    • 8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.2.3. U.S.
    • 8.2.3.1. Overview
    • 8.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.2.4. Canada
    • 8.2.4.1. Overview
    • 8.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 8.3. Europe
    • 8.3.1. Overview
    • 8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.3.3. France
    • 8.3.3.1. Overview
    • 8.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.3.4. Germany
    • 8.3.4.1. Overview
    • 8.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.3.5. Rest of Europe
    • 8.3.5.1. Overview
    • 8.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 8.4. Asia Pacific (APAC)
    • 8.4.1. Overview
    • 8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.4.3. China
    • 8.4.3.1. Overview
    • 8.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.4.4. India
    • 8.4.4.1. Overview
    • 8.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.4.5. Rest of APAC
    • 8.4.5.1. Overview
    • 8.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • 8.5. Rest of the World
    • 8.5.1. Overview
    • 8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.5.3. Latin America
    • 8.5.3.1. Overview
    • 8.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
    • 8.5.4. Middle East and Africa
    • 8.5.4.1. Overview
    • 8.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)

9. KEY VENDOR ANALYSIS

  • 9.1. Shire
    • 9.1.1. Company Overview
    • 9.1.2. SWOT Analysis
    • 9.1.3. Key Developments
  • 9.2. Octapharma
    • 9.2.1. Company Overview
    • 9.2.2. SWOT Analysis
    • 9.2.3. Key Developments
  • 9.3. CSL
    • 9.3.1. Company Overview
    • 9.3.2. SWOT Analysis
    • 9.3.3. Key Developments
  • 9.4. Grifols
    • 9.4.1. Company Overview
    • 9.4.2. SWOT Analysis
    • 9.4.3. Key Developments
  • 9.5. China Biologics Products, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. SWOT Analysis
    • 9.5.3. Key Developments

Client can request additional company profiling as per specific requirements

10. 360 DEGREE ANALYSTVIEW

11. APPENDIX

  • 11.1. Research Methodology
  • 11.2. Abbreviations
  • 11.3. Disclaimer
  • 11.4. Contact Us

List of Tables

  • Table 1 List of Acronyms
  • Table 2 Key Market Facts, 2014 - 2025
  • Table 3 Market Drivers: Impact Analysis
  • Table 4 Market Restraint: Impact Analysis
  • Table 5 Market Opportunity: Impact Analysis
  • Table 6 PESTLE Analysis
  • Table 7 Porter's Five Forces Analysis
  • Table 8 Company Market Share Analysis
  • Table 9 Global Intravenous Immunoglobulin Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Million)
  • Table 10 Intravenous Immunoglobulin Market, by Disease Types, 2014 - 2025 (USD Million)
  • Table 11 Intravenous Immunoglobulin Market, by Geography, 2014 - 2025 (USD Million)
  • Table 12 North America Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 13 U.S. Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 14 Canada Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 15 Europe Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 16 France Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 17 Germany Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 18 Asia Pacific Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 19 China Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 20 India Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 21 Latin America Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)
  • Table 22 MEA Intravenous Immunoglobulin Market, 2014 - 2025 (USD Million)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Research Process Flow Chart
  • Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
  • Figure 4 Regulatory Framework Analysis
  • Figure 5 Value Chain Analysis Analysis
  • Figure 6 Intravenous Immunoglobulin Market, by Disease Types, 2014 - 2025 (USD Million)
  • Figure 7 Intravenous Immunoglobulin Market, by Geography, 2014 - 2025 (USD Million)
Back to Top